Early detection of pancreatic carcinoma.
The poor prognosis and late presentation of pancreatic cancer patients emphasize the importance of an effective early detection strategy for patients at risk of developing pancreatic cancer. In current practice, the use of CA 19-9 levels and imaging techniques is not optimal for detecting small pancreatic lesions. It is hoped that the understanding of genetic alterations in combination with the development of high-throughput sensitive techniques will lead to the rapid discovery of a panel of biomarkers that will save lives by enabling aggressive therapy at the time when tumors are curable.
Rosty
Christophe
C
Department of Pathology, Johns Hopkins Medical Institutions, 720 Rutland Avenue, Baltimore, MD 21205-2196, USA.
Goggins
Michael
M
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D014408:Biomarkers, Tumor / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D004268:DNA-Binding Proteins; D003952:Diagnostic Imaging; D018450:Disease Progression; D016147:Genes, Tumor Suppressor; D006801:Humans; D006965:Hyperplasia; D008403:Mass Screening; D008954:Models, Biological; D009386:Neoplastic Syndromes, Hereditary / Q000235:genetics; D009857:Oncogenes; D010179:Pancreas / Q000473:pathology; D010189:Pancreatic Juice / Q000201:enzymology; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D040901:Proteomics; D012907:Smoking / Q000009:adverse effects; D019098:Telomerase / Q000032:analysis
D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D004268:DNA-Binding Proteins; D019098:Telomerase